Lithium is one of those molecules most people think they understand, until you zoom out. Yes, it’s a time-tested medication for bipolar disorder. But at tiny, trace doses, lithium starts to look like something else entirely: a potential micronutrient with outsized influence on mood stability, inflammation, and brain ageing.
We walk through why interest in low-dose lithium is rising in the brain health and longevity world, even as human clinical trials are still early. John and I talk about what lithium is chemically, why it’s so bioavailable, how it crosses the blood-brain barrier, and why the kidneys matter more at prescription doses than at supplement-scale milligrams. Then we connect the dots on mechanisms people care about most for neuroprotection: GSK-3 inhibition, support for BDNF, a tilt toward calming inhibitory signalling (GABA), better balance in serotonin pathways, and less glutamate-driven mitochondrial stress.
We also wrestle with the bigger public health angle: what happens when we treat chronic disease as “too much of everything” and ignore deficiency and nourishment. Soil mineral depletion, variable food mineral content, and strong population associations with lithium in drinking water (including mental health measures and Alzheimer’s mortality) make this a conversation worth having, carefully and objectively.
If this sparks questions for you, subscribe, share it with a friend, and leave a review so more people can find the show.
Beyond its Psychiatric Use- The Benefits of Low-dose Lithium Supplementation
Lithium Promotes Longevity through GSK3_NRF2- Dependent Hormesis